Descartes-25 in Relapsed/Refractory Multiple Myeloma

Summary

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.

Timeline

Start

2021-11-25

Primary completion

2023-05-09

Completion

2024-11-08

Outcome

Outcome not reported

Stopped (Enrollment): “Phase 1 enrollment completed. Further clinical development terminated.”

Drugs

Indications